We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Personalized Trial in ctDNA-level-relapse Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05539339
Recruitment Status : Not yet recruiting
First Posted : September 14, 2022
Last Update Posted : September 27, 2022
Information provided by (Responsible Party):
Henan Provincial People's Hospital

Brief Summary:
Tumor in situ fluid (TISF) refers to the fluid within the surgical cavity of patients with glioblastoma. Postoperative serial TISF is collected for circulating tumor DNA (ctDNA) analysis and identifying ctDNA-level relapse driven by one or a set of specific genomic alterations before overt imaging recurrence of the tumor. This single-arm open-label prospective pilot feasibility trial recruiting 20 adult patients with ctDNA-level-relapse glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their serial TISF ctDNA. It will be aimed to test whether the personalized intervention can prolong the progression-free and overall survival and the feasibility of conducting a full-scale trial.

Condition or disease Intervention/treatment Phase
Glioblastoma Other: Individualized intervention based on genomic alterations Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, pilot, umbrella trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Molecular Profiling of Tumor in Situ Fluid in Guiding Individualized Treatment Plan in Adults With ctDNA-level-relapse Glioblastoma
Estimated Study Start Date : December 1, 2022
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : June 1, 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1
This arm includes patients with ctDNA-level-relapse glioblastoma before imaging recurrence.
Other: Individualized intervention based on genomic alterations
Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.

Primary Outcome Measures :
  1. Progression-free survival at 6 months [ Time Frame: Up to six months after beginning treatment ]
    The proportion of participants in the analysis population who remain progression-free for at least six months following initiation of study therapy.

  2. Overall survival rate at 18 months [ Time Frame: Up to 18 months after beginning therapy ]
    OS-18 is the proportion of participants in the analysis population who remain alive for at least twelve months following initiation of study therapy.

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Up to 3 years after beginning treatment ]
    overall survival, as defined as time from beginning of treatment to death.

  2. Progression-free survival [ Time Frame: Up to 3 years after beginning treatment ]
    Median time from allocation to first documented disease progression as per the response assessment in neuro-oncology criteria or death due to any cause, whichever occurs first.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent and HIPAA authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by MRI and tumor in situ fluid (TISF) collection
  3. Histologically confirmed diagnosis of glioblastoma
  4. Resection surgery done at the study center (Henan Provincial People's Hospital), with a reservoir intraoperatively implanted connecting the surgical cavity and the subscalp for postoperative noninvasive TISF collection
  5. Previous first line treatment with at least radiotherapy
  6. An interval of > 28 days and full recovery (i.e., no ongoing safety issues) from surgical resection prior to grouping
  7. Karnofsky performance status (KPS) of 70 or higher
  8. Life expectancy > 12 weeks

Exclusion Criteria:

  1. More than two recurrences of GBM
  2. Presence of extracranial metastatic, significant leptomeningeal disease or tumors primarily localized to the brainstem or spinal cord
  3. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
  4. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring chronic and systemic immunosuppressive treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects have any other condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days. Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone equivalent are permitted in absence of active autoimmune disease
  5. Previous radiation therapy with anything other than standard radiation therapy (i.e., focally directed radiation) administered as first line therapy
  6. Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization
  7. Previous bevacizumab or other VEGF or anti-angiogenic treatment
  8. Previous treatment with a PD-1, PD-L1 or CTLA-4 targeted therapy
  9. Evidence of > Grade 1 CNS hemorrhage on the baseline MRI scan
  10. Inadequately controlled hypertension (defined as systolic blood pressure ≥160 mmHg and /or diastolic blood pressure ≥100 mmHg) within 7 days of first study treatment
  11. Prior history of hypertensive crisis, hypertensive encephalopathy, reversible posterior leukoencephalopathy syndrome (RPLS)
  12. Prior history of gastrointestinal diverticulitis, perforation, or abscess
  13. Clinically significant (i.e., active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
  14. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment. Any previous venous thromboembolism ≥ NCI CTCAE Grade 3 within 3 months prior to start of study treatment
  15. History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month prior to randomization
  16. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
  17. Current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding. Prophylactic use of anticoagulants is allowed
  18. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
  19. Minor surgical procedure (e.g., stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)
  20. History of intracranial abscess within 6 months prior to randomization;
  21. History of active gastrointestinal bleeding within 6 months prior to randomization
  22. Serious, non-healing wound, active ulcer, or untreated bone fracture
  23. Subjects unable (due to existent medical condition, e.g., pacemaker or ICD device) or unwilling to have a head contrast enhanced MRI
  24. Positive test for hepatitis B virus surface antigen (HBV sAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection
  25. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  26. History of severe hypersensitivity reaction to any monoclonal antibody
  27. Patients that require decadron > 4 mg/ day or equivalent of steroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05539339

Layout table for location contacts
Contact: Xingyao Bu, MD, PhD +86037165580295 xingyaob@zzu.edu.cn
Contact: Zhiyuan Sheng, MD +86037165580295 zhiyuan.sheng22@gmail.com

Layout table for location information
China, Henan
Henan Provincial People's Hospital
Zhengzhou, Henan, China, 450003
Sponsors and Collaborators
Henan Provincial People's Hospital
Layout table for investigator information
Study Director: Xingyao Bu, MD, PhD Henan Provincial People's Hospital
Layout table for additonal information
Responsible Party: Henan Provincial People's Hospital
ClinicalTrials.gov Identifier: NCT05539339    
Other Study ID Numbers: HPPH-ttrGBM
First Posted: September 14, 2022    Key Record Dates
Last Update Posted: September 27, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue